Resveratrol inhibits transforming growth factor-β2-induced epithelial-to-mesenchymal transition in human retinal pigment epithelial cells by suppressing the Smad pathway

by Chen CL, Chen YH, Tai MC, Liang CM, Lu DW, Chen JT
Published 2017-01-01

Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication

by Huang HT, Wang HM, Yang SC, Tai WC, Liang CM, Wu KL, Lee CH, Chuah SK
Published 2018-10-01

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical P...

by Hung KT, Yang SC, Wu CK, Wang HM, Yao CC, Liang CM, Tai WC, Wu KL, Kuo YH, Lee CH, Chuah SK
Published 2021-03-01

First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus

by Yao CC, Kuo CM, Hsu CN, Yang SC, Wu CK, Tai WC, Liang CM, Wu KL, Huang CF, Bi KW, Lee CH, Chuah SK
Published 2019-05-01

Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective random...

by Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Yao CC, Tsai CE, Liang CM, Wang YK, Wang JW, Huang CF, Chuah SK
Published 2019-04-01

A Comparison Between Dexlansoprazole Modified Release–Based And Lansoprazole-Based Nonbismuth Quadruple (Concomitant) Therapy For First-Line Helicobacter pylori Eradication:...

by Tai WC, Liang CM, Bi KW, Kuo CM, Lu LS, Wu CK, Yang SC, Kuo YH, Lee CH, Huang CF, Hsu CN, Hsu PI, Wu DC, Hu TH, Wu KL, Chuah SK
Published 2019-09-01

A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication:...

by Tai WC, Liang CM, Bi KW, Kuo CM, Lu LS, Wu CK, Yang SC, Kuo YH, Lee CH, Huang CF, Hsu CN, Hsu PI, Wu DC, Hu TH, Wu KL, Chuah SK
Published 2019-09-01